TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [5]

Active Indication

Locally Advanced Malignant Solid NeoplasmNTRK fusion-positive solid tumorsNeoplasms+ [12]

Inactive Indication-

Originator Organization

Array BioPharma, Inc.

Bayer AG

Loxo Oncology, Inc.

Active Organization

Bayer AGBayer Australia Ltd.

University of Calgary

+ [4]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (26 Nov 2018),

Solid tumor

RegulationAccelerated Approval (US), Conditional marketing approval (CN), Orphan Drug (KR), Breakthrough Therapy (US), Orphan Drug (US)

Structure/Sequence

Molecular FormulaC21H24F2N6O6S

InChIKeyPXHANKVTFWSDSG-QLOBERJESA-N

CAS Registry1223405-08-0

Clinical Trials associated with Larotrectinib Sulfate

NCT06563999

/ RecruitingPhase 2IIT

Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)

This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.

Start Date01 Nov 2024

Sponsor / Collaborator

Sun Yat-Sen University

NCT05783323

/ RecruitingPhase 2IIT

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

Start Date14 Feb 2024

Sponsor / Collaborator

The Children's Hospital of Philadelphia

[+1]

NCT05725200

/ RecruitingPhase 2IIT

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Start Date27 Sep 2022

Sponsor / Collaborator

Oslo universitetssykehus HF

100 Clinical Results associated with Larotrectinib Sulfate

100 Translational Medicine associated with Larotrectinib Sulfate

100 Patents (Medical) associated with Larotrectinib Sulfate

388

Literatures (Medical) associated with Larotrectinib Sulfate

01 Apr 2025·ANNALES D ENDOCRINOLOGIE

Choroidal metastasis secondary to follicular thyroid carcinoma successfully managed with larotrectinib: A case report and review of the literature

Letter

Author: García-Arumí, Claudia ; Bertolani, Yann ; Goncharova, Tetiana ; Arnaiz-Camacho, Albert ; García-Arumí, Jose

01 Jan 2025·NEUROPHARMACOLOGY

The engagement of Ras/Raf/MEK/ERK and PLCγ1/PKC pathways regulated by TrkB receptor in resistance of glioma cells to elimination upon apoptosis induction

Article

Author: Rzeski, Wojciech ; Zając, Adrian ; Jakubowicz-Gil, Joanna ; Sumorek-Wiadro, Joanna ; Maciejczyk, Aleksandra ; Wertel, Iwona ; Chojnacki, Michał

The most aggressive tumors of human central nervous system are anaplastic astrocytoma (AA, III grade) and glioblastoma multiforme (GBM, IV grade) with an extremely bad prognosis. Their malignant character and resistance to standard therapy are correlated to the over-expression of survival pathways such as Ras/Raf/MEK/ERK and PLCγ1/PKC regulated by TrkB receptor. Therefore, the aim of this study was to investigate the engagement of those pathways in human glioma cells resistance for apoptosis induction by Temozolomide treatment. Two cancer MOGGCCM (AA) and T98G (GBM) and normal human astrocytes (NHA) cell lines were utilized. The tested inhibitors single and simultaneous action with Temozolomide affection on apoptosis induction was analyzed by MTT, microscopic observations and flow cytometry. Bcl-2:beclin-1 complexes occurrence was also assessed. siRNAs were used for direct proof of tested pathways engagement in gliomas resistance to apoptosis elimination. The most effective in eliminating gliomas with minimal astrocyte damage was 5 μM PLCγ1 inhibitor (U-73122) for MOGGCCM and 15 μM for T98G cells, and 1 μM LOXO-101 for all cancer cells. Sorafenib, Temozolomide, U-73122, and LOXO-101 effectively eliminate cancer cells. Single applications of sorafenib and Temozolomide were effective, but had lower efficiency than U-73122 and LOXO-101. These drugs induced apoptosis, affecting mitochondrial membrane potential and caspases 3, 8, and 9 activity. The study found that a Bcl-2:beclin-1 complex formation was observed when apoptosis was dominant. Inhibiting the pathways regulated by TrkB receptor combined with Temozolomide action, led to successful gliomas elimination. Those results might serve as basis for modern targeted treatment development.

20 Dec 2024·Journal of biomolecular structure & dynamics

Evaluation of the FDA-approved kinase inhibitors to uncover the potential repurposing candidates targeting ABC transporters in multidrug-resistant cancer cells: an in silico approach

Article

Author: Moosavi, Fatemeh ; Poustforoosh, Alireza

Multiple drug resistance (MDR) is characterized by the resistance of cancer cells to a broad spectrum of anticancer drugs. The main mechanism underlying the MDR phenotype is the overexpression of ATP-binding cassette (ABC) transporters by promoting active drug efflux from cancer cells. Some small-molecule protein kinase inhibitors have been found to overcome MDR by inhibiting ABC transporters as substrates or modulators. This study investigated the chemical activity of 58 FDA-approved anticancer kinase inhibitors against three multidrug resistance-related proteins. The studied proteins are ATP-Binding Cassette Sub-Family B Member 1 (ABCB1), ATP-Binding Cassette Subfamily C Member 1 (ABCC1), and ATP-binding cassette superfamily G member 2 (ABCG2). The drug-binding domain and ATP binding sites of the proteins were considered the kinase inhibitors' probable target. High-throughput virtual screening and molecular docking were employed to find the hit drugs, and the drugs with the highest binding affinity were further evaluated using the molecular dynamics (MD) simulation. The virtual screening revealed that several kinase inhibitors could be considered potential inhibitors of ABCB1, ABCC1, and ABCG2, among which larotrectinib, entrectinib, and infigratinib showed the highest binding affinity, respectively. Based on the obtained results from MD simulation, these drugs can form strong interactions with the essential residues of the target proteins. In silico investigation revealed that larotrectinib, entrectinib, and infigratinib can target the key residues of the studied proteins. Therefore, these approved kinase inhibitors could be considered potential therapies for MDR cancers by targeting these transporters.Communicated by Ramaswamy H. Sarma.

News (Medical) associated with Larotrectinib Sulfate

23 Dec 2024

·www.globenewswire.com

Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis

In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assaysOGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotypingWhen OGM results and next-generation sequencing (NGS) results were combined, diagnostic and pathogenic structural variants (SVs), copy number variants (CNVs), and/or single nucleotide variants (SNVs) were found in ~98% of cases, a substantially greater rate than when karyotyping, FISH and NGS are used SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors. Key findings: OGM detected all variants revealed by conventional cytogenetics: OGM showed 100% concordance, identifying all pathogenic variants detected by standard of care cytogenetic methods. The specificity of OGM was assessed to be 100%, i.e. OGM correctly identified the same pathogenic SVs and CNVs detected by standard of care/routine cytogenetics (karyotyping and FISH).OGM detected pathogenic variants missed by karyotyping: In 74% of cases with normal or failed karyotype, OGM detected diagnostic or pathogenic SVs that were missed by karyotyping. Further, in 6 cases that failed to yield any karyotyping results due to culture failure, OGM detected pathogenic SVs in all of them. Variants found by OGM but missed by standard of care included the EWSR1::ETV1 fusion, which is a key molecular hallmark of clear cell sarcoma and helps to differentiate it from other soft tissue sarcomas and melanomas.OGM resolved complex cancer genomes: Study authors found that OGM data could re-characterized and better defined complex structural rearrangements including chromoanagenesis in 27% of cases and complex 3-6-way translocations in 15% of cases when compared to traditional cytogenetic methods.OGM combined with NGS found pathogenic variants in 98% of cases, a substantially greater rate than when karyotyping, FISH and NGS are used: The integrated approach of the combination of OGM and NGS resulted in the detection of pathogenic SVs and sequence variants in ~98% of cases. OGM was 100% concordant with NGS for aneuploidy detection.OGM findings have the potential to qualify subjects for targeted therapies that otherwise would not have been possible: The authors state that several of the OGM findings could result in the potential for these cases to qualify for either targeted treatments or clinical trials. For example, cases with potential to be treated by CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), TRK inhibitors (larotrectinib, entrectinib), pan-FGFR inhibitors (erdafitinib or futibatinib) were highlighted. Erik Holmlin, president and chief executive officer of Bionano commented, “Approximately 50% of bone and soft tissue tumor samples fail to reveal actionable information for proper classification of disease, prognosis and therapeutic management because they either fail to culture or because traditional techniques in cytogenetics lack adequate sensitivity and specificity to reliably detect relevant variants. We have seen increasing evidence for OGM as a valuable alternative to cytogenetic methods in blood cancers, and we are thrilled to see researchers at Johns Hopkins publishing this compelling case for extending OGM’s utility to bone and soft tissue tumors.” The full research publication is available at: https://doi.org/10.1016/j.modpat.2024.100684 About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com or www.bionanolaboratories.com. Bionano’s products are for research use only and not for use in diagnostic procedures. Forward-Looking Statements of Bionano Genomics This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “could,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility for applications in bone and soft tissue cancers; OGM’s ability to detect SVs and CNVs concordant with traditional cytogenetic methods, including karyotyping and FISH; OGM’s ability to detect SVs and CNVs not detected with transitional cytogenetic methods; the utility and ability of OGM to detect diagnostically relevant or pathogenic SVs and CNVs; the ability of OGM and NGS in combination to detect more SVs than when combining karyotyping, FISH and NGS; the potential for OGM to be useful in qualifying subjects for targeted therapies or clinical trials; the utility of OGM for uses described in the publication referenced in this press release; the ability of OGM to re-characterized and better defined complex structural rearrangements when compared to traditional cytogenetic methods; OGM’s ability and utility for adoption across a wider spectrum of cancers including blood, bone and soft tissue cancers and the increase in adoption and utilization as an alternative to traditional cytogenetic methods; the utility of OGM for applications in areas reported in this press release; and other statements that are not historical facts. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, supply chain disruptions, global pandemics, inflation, and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to prove useful for applications in bone and soft tissue cancers; the failure of OGM to detect SVs concordant with traditional cytogenetic methods, including karyotyping and FISH; the failure of OGM to detect SVs and CNVs not detected with transitional cytogenetic methods; the failure of OGM to detect diagnostically relevant or pathogenic SVs and CNVs; the failure of OGM to prove useful for applications described in the publication referenced in this press release; the failure of OGM to be more widely adopted across a wider spectrum of cancers including blood, bone and soft tissue cancers and the increase in adoption and utilization as an alternative to traditional cytogenetic methods; the failure of OGM and NGS in combination to detect more SVs than when combining karyotyping, FISH and NGS; the failure of OGM to be useful in qualifying subjects for targeted therapies or clinical trials; the failure of OGM to prove useful for applications in areas reported in this press release; the failure of OGM to re-characterized and better defined complex structural rearrangements when compared to traditional cytogenetic methods future publications that contradict the findings of the publication referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com

Oligonucleotide

09 Dec 2024

·www.prnewswire.com

Children's Hospital of Philadelphia Researchers Find Precision Medicine Treatment Delivers Strong Results for Infantile Fibrosarcoma and Other Solid Tumors

Study demonstrated that a previously approved drug could replace chemotherapy as a first-line therapy for certain cancers PHILADELPHIA, Dec. 9, 2024 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) found that larotrectinib, an oral drug that stops cancer-cell growth, was highly effective in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) or other solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. The study, published today in the Journal of Clinical Oncology, is the first COG trial to test precision medicine in a front-line setting across all different types of solid tumors based on a genetic biomarker rather than histology. It is poised to redefine the approach to treatment for newly diagnosed fibrosarcoma and other solid tumors with the NTRK gene fusion, potentially reducing or eliminating the need for these patients to receive chemotherapy. Continue Reading Theodore W. Laetsch, MD "Precision medicine is transforming pediatric cancer care, offering tailored treatments that bring new hope for better outcomes and a brighter future for children and their families," said Theodore W. Laetsch, MD, the lead study author and a pediatric oncologist at CHOP, who leads the hospital's Developmental Therapeutics Program and Very Rare Malignant Tumors Program, as well as holding national leadership roles in each of these areas within COG. IFS, a rare soft-tissue sarcoma, typically presents as a localized tumor. Although surgery often cures IFS, infants frequently present with fast-growing tumors that can't be removed with surgery and require chemotherapy, which can pose serious harm to a young child's developing organs and tissues. Larotrectinib was approved in 2018 by the U.S. Food and Drug administration (FDA) for pediatric and adult patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to have severe side effects, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. Unlike traditional treatments directed at specific cancers based on their location in the body, larotrectinib targets the NTRK fusion present in the tumor, making it effective across various cancer types that share this mutation. Researchers have previously conducted front-line research of precision medicines for neuroblastoma and Ewings sarcoma, however, this is the first study to enroll patients with any cancer based on a specific genetic mutation. In this study, researchers analyzed 33 patients between October 2019 and July 2022: 18 with IFS and 15 with other solid tumors. The patients, whose median age was 8, received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and whether the tumor could be safely removed with surgery. The primary end point was the objective response rate (ORR) within six cycles in patients with IFS, which refers to the percentage of patients whose cancer shrinks or disappears completely after treatment based on medical tests. Secondary objectives included event-free survival (EFS) and overall survival (OS). The ORR within six cycles was 94% among children with IFS and 60% among children with other solid tumors. Two patients, one with IFS and one with a different solid tumor, experienced disease progression while on the therapy and eventually died of their disease. The two-year EFS and OS among these groups were 82.2% and 93.8% for IFS and 80% and 93.3% for other solid tumors. Patients undergoing surgical resection of their tumor had prolonged EFS. "This trial cements larotrectinib as the frontline therapy for patients with newly diagnosed fibrosarcoma and other solid tumors that also possess an NTRK gene fusion," said Laetsch, who is also a member of the cellular therapy/chimeric antigen receptor (CAR) T-cell team at CHOP. "Our goal is always to present the safest and most effective treatment approach for our patients, which includes sparing them from the short and long-term complications of chemotherapy." The research was supported by an NCTN Operations Center Grant (U10CA180886), NCTN Statistics & Data Center Grant (U10CA180899), COG Biospecimen Bank Grant (U24CA196173), St Baldrick's Foundation, Alex's Lemonade Stand Foundation, and Bayer. Laetsch is a consultant for Bayer, manufacturer of larotrectinib. Laetsch et al. "Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors." J Clin Oncol. Online December 9, 2024. DOI: 10.1200/JCO-24-01854. About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit . Contact: Jennifer Lee Children's Hospital of Philadelphia (267) 426-6084 [email protected] SOURCE Children's Hospital of Philadelphia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalClinical StudyClinical ResultCell Therapy

28 Aug 2024

·www.fiercebiotech.com

FDA approves Illumina's tumor biomarker test as a pan-cancer companion diagnostic

Illumina said it “has a growing pipeline” of companion diagnostic claims under development, through collaborations with drugmakers. Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores.A version of the company’s TruSight Oncology Comprehensive genomic diagnostic kit has been available in Europe since 2022. The test screens solid tumor samples for 517 different genes to uncover useful biomarker patterns that can identify patients who may benefit from specific immunotherapies.That includes Bayer’s Vitrakvi (larotrectinib)—for adult and pediatric patients with certain NTRK mutations, regardless of their type of cancer—as well as Eli Lilly's Retevmo (selpercatinib) among people with RET fusion-positive non-small cell lung cancer (NSCLC). The latter is a new addition compared to the EU version of the test.Those green lights, according to Illumina, make TSO Comprehensive the first FDA-approved, genomic in vitro diagnostic kit to carry pan-cancer companion diagnostic claims. The test, which runs on the company’s NextSeq 550Dx instrument, also provides measures of tumor mutational burden and other profiling information. “FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community,” Illumina’s chief commercial officer, Everett Cunningham, said in a statement.NTRK gene fusions may only be found in about 0.1% to 0.3% of solid tumors and can be difficult to detect on top of that, Illumina said. By scanning RNA as well as DNA, the test can find multiple forms of the biomarker. Vitrakvi was one of the first pan-cancer therapies, garnering an FDA approval in 2018, but Bayer has at times struggled to find eligible patients for the targeted therapy.At the same time, RET fusion-positive mutations occur in less than 2% of NSCLC cases. Retevmo has also shown gains in genomically related thyroid cancers, and the FDA expanded the drug’s indications in September 2022 to include all solid tumors presenting the RET biomarker—however, TSO Comprehensive’s companion diagnostic claims are limited to NSCLC.Illumina said it “has a growing pipeline” of companion diagnostic claims currently under development, in collaboration with drugmakers, that it will seek in future regulatory submissions.

ImmunotherapyDiagnostic ReagentsDrug ApprovalClinical StudyClinical Result

100 Deals associated with Larotrectinib Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D11138	Larotrectinib Sulfate	L01XE53	DB14723

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Locally Advanced Malignant Solid Neoplasm	AU	Bayer Australia Ltd.	07 Sep 2020
NTRK fusion-positive solid tumors	EU	Bayer AG	19 Sep 2019
NTRK fusion-positive solid tumors	IS	Bayer AG	19 Sep 2019
NTRK fusion-positive solid tumors	LI	Bayer AG	19 Sep 2019
NTRK fusion-positive solid tumors	NO	Bayer AG	19 Sep 2019
Neoplasms	CA	Bayer, Inc.	10 Jul 2019
Solid tumor	US	Bayer HealthCare Pharmaceuticals, Inc.	26 Nov 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 2	US	Bayer AG	14 Feb 2024
Advanced Malignant Solid Neoplasm	Phase 2	US	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	CN	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	JP	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	AR	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	AU	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	BE	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	BR	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	CA	Bayer AG	30 Sep 2015
Advanced Malignant Solid Neoplasm	Phase 2	CO	Bayer AG	30 Sep 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2024	Not Applicable	Neoplasms tropomyosin receptor kinase fusion-positive	-	Larotrectinib	oddzzhlhfj(mljmbnaeij) = vgsddbyrnd qasdxwoyhz (hnhpfetndj ) View more	Positive	07 Dec 2024
ESMO_ASIA2024	Not Applicable	Neoplasms tropomyosin receptor kinase fusion-positive	-	larotrectinib (Standard of Care (SoC))	oddzzhlhfj(mljmbnaeij) = kkpnqelsdp qasdxwoyhz (hnhpfetndj ) View more	Positive	07 Dec 2024
ESMO_ASIA2024	Not Applicable	NTRK fusion-positive solid tumors NTRK fusion-positive	-	Larotrectinib	nmnfzdutyz(ovzsyittrb) = xycsyuiawh duglnkbelr (tergihvjdt ) View more	Positive	07 Dec 2024
NCT02576431 \| NCT02637687 (CTNI-07, SNO2024)	Not Applicable	NTRK fusion-positive Central Nervous System Neoplasms	55	Larotrectinib	ibiktckmbr(hrjddxmthd) = ovcaztfqfr vhpjdilogs (lagagdabyu ) View more	Positive	11 Nov 2024
ESMO2024 Manual	Not Applicable	Recurrent Glioblastoma BRAF V600E	17	Dabrafenib-trametinib	lotnbkpsja(xblksclyvy) = None ompphknfbu (ovqyyxjrmt )	Positive	16 Sep 2024
ESMO2024 Manual	Not Applicable	Recurrent Glioblastoma BRAF V600E	17	Larotrectinib	lotnbkpsja(xblksclyvy) = None ompphknfbu (ovqyyxjrmt )	Positive	16 Sep 2024
NCT02576431 \| NCT02637687 \| NCT02122913 (SCOUT, ESMO2024) Manual	Phase 1/2	Neoplasms First line NTRK gene fusions	100	Larotrectinib	gglfagsyrl(fkedatuioo) = htosmddpsy tpdpgrdvem (tbxiqhktnc, 65 - 86) View more	Positive	14 Sep 2024
	Phase 1/2	Neoplasms First line NTRK gene fusions	100	Larotrectinib (adults)	scxqjnbntk(ldhgaozkzi) = vjkpujfhdx lriomgboti (krdnvowxnb, 54 - 79)	Positive	14 Sep 2024
NCT02576431 \| NCT02637687 \| NCT02122913 (SCOUT, ESMO2024) Manual	Phase 1/2	Central Nervous System Neoplasms NTRK gene fusions	302	Larotrectinib	gpsvkbkpop(nqnalyvxys) = ojcqsxpcms naqvefxlyq (ecpjmatfil, 59 - 70) View more	Positive	14 Sep 2024
NCT02576431 \| NCT02122913 (WCLC2024) Manual	Phase 1/2	Lung Cancer NTRK Rearrangement	32	Larotrectinib 100 mg	nnlikumjvy(raygmxnxcu) = mqluxhvwdc jgolgqoalb (zbitheeboe ) View more	Positive	10 Sep 2024
NCT05192642 (VICTORIA, ASCO2024) Manual	Not Applicable	Neoplasms TRK fusion	164	Larotrectinib	ubkntzpawk(bqndrmvdhb) = ytbwtvoekv ncbmpcbyqe (iptmjcfhmu ) View more	Positive	24 May 2024
NCT05192642 (VICTORIA, ASCO2024) Manual	Not Applicable	Neoplasms TRK fusion	164	Non-TRK inhibitor therapies	ubkntzpawk(bqndrmvdhb) = ykzkixjsvb ncbmpcbyqe (iptmjcfhmu ) View more	Positive	24 May 2024
NCT02576431 \| NCT02122913 (ASCO2024) Manual	Phase 1/2	Lung Cancer TRK fusion	32	Larotrectinib 100 mg	wcbbhsclwv(arppmpzvet) = Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. cyqcrrbnfc (qnduyxchyh )	Positive	24 May 2024
ASCO2024 Manual	Not Applicable	NTRK fusion-positive solid tumors NTRK1 \| NTRK3 \| NTRK2	21	Larotrectinib	ausdghquok(cfmcglvifj) = wyvjzmixbt sgvgqmehgx (bfybmlihal ) View more	Positive	24 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis